Doctors order a PSEN1 genetic test when someone under about age 65 develops progressive memory loss and has a family history of early-onset dementia. PSEN1 is the most frequently mutated of the three known genes that cause inherited, autosomal-dominant Alzheimer's disease, so clinicians sequence it first when a younger patient's symptoms and family pattern point toward a genetic cause (Scientific Reports, 2020). The test matters because PSEN1-related Alzheimer's behaves differently than the common late-onset form. Mutations in this gene produce the youngest average age of symptom onset among the three familial Alzheimer's genes, typically between roughly 30 and 50 years old, decades earlier than typical Alzheimer's (Scientific Reports, 2020).
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Should Be Tested
- Testing Relatives Who Have No Symptoms
- What a Result Does and Doesn't Tell You
- Genetic Counseling Before and After the Test
- Does Insurance Cover PSEN1 Testing?
- Frequently Asked Questions
Who Should Be Tested
A published genetic-counseling guideline lays out specific circumstances for offering PSEN1 testing alongside its related genes, PSEN2 and APP. Testing should be offered to a symptomatic person with early-onset Alzheimer's disease when the family has a known history of dementia, when the family history is unknown (as with adoption), or when the family shows an autosomal-dominant pattern with one or more early-onset cases (GuidelineCentral). Commercial laboratories apply the same logic in practice.
Testing is considered appropriate for someone with early-onset dementia who has at least one affected relative, and separately, to confirm carrier status in relatives of a person already known to carry a familial PSEN1 variant (PreventionGenetics). PSEN1 is also the gene most likely to be found when a younger patient's memory symptoms cluster in a dominant-inheritance family. It accounts for a large share, cited variously at roughly 20% to 70%, of early-onset familial Alzheimer's disease cases, which is why it is typically the first gene sequenced in this clinical picture (LabTestsOnline UK).
Testing Relatives Who Have No Symptoms
PSEN1 testing is not limited to people who already have memory problems. The same guideline supports offering testing to an asymptomatic or minimally symptomatic relative once a family member is confirmed to carry a PSEN1 mutation. Each child of a known carrier has a 50% chance of inheriting the mutation, which is why relatives often seek testing before any symptoms appear (GuidelineCentral).
This predictive use raises different stakes than diagnostic testing in a symptomatic patient, because a positive result in a healthy person forecasts a future disease rather than explaining a current one. Guidance explicitly warns genetic counselors to watch for situations where a relative, rather than the person being tested, is pushing for the test, and advises against proceeding if the person who would be tested appears averse to it. Testing decisions are meant to center on that individual's autonomy, not family pressure (GuidelineCentral).
What a Result Does and Doesn't Tell You
A positive PSEN1 result in a symptomatic younger patient confirms a genetic, inherited cause for the memory loss and identifies which relatives face the 50% inheritance risk described above. For a healthy relative, a positive result means a future diagnosis is highly likely, while a negative result means that specific inherited risk does not apply to them.
A negative PSEN1 result in a symptomatic patient does not close the case. Other genes, PSEN2 and APP, or variants not yet discovered, can still cause early-onset familial Alzheimer's disease, so a negative finding does not rule out a heritable cause (Pathology Tests Explained / LabTestsOnline UK). Doctors typically weigh whether further genetic workup is warranted based on how strongly the family history still points to an inherited pattern.
Genetic Counseling Before and After the Test
Every source on PSEN1 testing recommends professional genetic counseling both before and after the test. Counseling prepares patients and families for the possibility of a positive result, particularly in the predictive-testing scenario where a healthy relative may learn they will likely develop dementia years before any symptoms appear (Highmark Commercial Medical Policy L-175-004).
This counseling requirement is not just a best practice; at least one insurer, Highmark, makes documented pre- and post-test counseling a condition of coverage for the test itself. Counseling sessions typically cover what a result will and won't mean, who else in the family may be affected, and how the person being tested wants to handle that information going forward.
Does Insurance Cover PSEN1 Testing?
Coverage depends heavily on who is being tested and why. Blue Shield of California's medical policy, effective December 2023, treats PSEN1, PSEN2, and APP testing as medically necessary mainly in two situations: a symptomatic early-onset case, or an at-risk relative of a confirmed carrier (Blue Shield of California).
Outside those two situations, the same policy classifies broader genetic risk screening of asymptomatic people as investigational and does not cover it. A patient considering testing should confirm with their insurer, before the blood draw, whether their specific clinical situation matches one of the covered scenarios or falls into the uncovered, investigational category.
- Symptomatic, early-onset memory loss with a family history of dementia: typically covered.
- Asymptomatic relative of a confirmed PSEN1 carrier: typically covered.
- General genetic risk screening with no qualifying family history or known carrier: typically classified as investigational, and not covered.
Frequently Asked Questions
Can someone be tested for PSEN1 if they don't know their family history?
Yes. The genetic-counseling guideline supports offering testing to a symptomatic early-onset patient when family history is unknown, such as in adoption cases (GuidelineCentral).
Does a negative PSEN1 test mean Alzheimer's isn't inherited in this family?
No. A negative result doesn't rule out PSEN2, APP, or an undiscovered variant as the cause (Pathology Tests Explained / LabTestsOnline UK).
Will insurance pay for predictive testing of a healthy relative?
Blue Shield of California's policy covers it when the relative is at risk from a confirmed carrier in the family, but not for general screening outside that scenario (Blue Shield of California).
